Evaluating the Efficacy and Safety of QL0911 in the Prevention of Chemotherapy- Induced Thrombocytopenia

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 8, 2022

Primary Completion Date

February 20, 2024

Study Completion Date

February 20, 2024

Conditions

Chemotherapy-induced Thrombocytopenia

Interventions

DRUG

QL0911

This study is designed to study QL0911 for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients receiving chemotherapy for cancer

DRUG

Placebo

Placebo comparator

Trial Locations (1)

Shanghai East Hospital, Shanghai

All Listed Sponsors

lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY